Innovate Biopharma Announces Analyst Event on Monday, May 20, 2019, in San Diego
09 Mayo 2019 - 7:01AM
Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT), a
clinical stage biotechnology company focused on developing novel
therapeutics for immuno-inflammatory disease, announced that it
plans to host an Analyst Event on Monday, May 20, 2019, in San
Diego, CA.
The event is intended to provide clinical and operational
progress updates, including details regarding the company’s Phase 3
celiac disease clinical trial.
|
Event: |
Innovate
Analyst Event |
|
Date: |
Monday, May 20, 2019 |
|
Time: |
1:00pm-2:00pm (Pacific Time) / 4:00pm-5:00pm (Eastern
Time) |
|
Location: |
Hilton San Diego Gaslamp Quarter - Pacific Meeting
Room401 K Street, San Diego, CA 92101 |
|
Webcast Link: |
Innovate Analyst Event |
|
Dial in: |
877-705-2969 |
Management will be available for one-on-one meetings with the
financial and scientific communities during the DDW event.
To attend the Innovate Analyst Event or to book an individual
appointment, please contact Jennifer K. Zimmons, Ph.D. at +1
917.214.3514 or jzimmons@innovatebiopharma.com.
Innovate intends to make available a live webcast and subsequent
replay of the event on its website. To access the webcast, please
visit the tab in the Events and Presentations section of Innovate’s
investor relations website.
About Innovate Biopharmaceuticals, Inc. (Nasdaq:
INNT)
Innovate is a clinical stage biotechnology company focused on
developing novel therapeutics for autoimmune and inflammatory
diseases. Innovate’s lead drug candidate, larazotide acetate, has a
mechanism of action that renormalizes the dysfunctional intestinal
barrier by decreasing intestinal permeability and reducing antigen
trafficking, such as gliadin fragments in celiac disease, and
bacterial toxins and immunogenic antigens in nonalcoholic
steatohepatitis (NASH). In several diseases, including celiac
disease, NASH, Crohn’s disease, ulcerative colitis, irritable bowel
syndrome (IBS), type 1 diabetes mellitus (T1DM), chronic kidney
disease (CKD), the intestinal barrier is dysfunctional with
increased permeability.
Forward Looking Statements
This press release includes forward-looking statements
including, but not limited to, statements related to the
development of drug candidates, our operations and business
strategy, capital raising, our expected financial results, and
corporate updates. The forward-looking statements contained in this
press release are based on management’s current expectations and
are subject to substantial risks, uncertainty and changes in
circumstances. Actual results may differ materially from those
expressed by these expectations due to risks and uncertainties,
including, among others, those related to our ability to obtain
additional capital on favorable terms to us, or at all, including,
without limitation, to fund our current and future preclinical
studies and clinical trials, including, without limitation, raising
additional funds for our Phase 3 registration trial for INN-202,
and the success, timing and cost of our drug development program
and our ongoing or future preclinical studies and clinical trials,
including, without limitation, the possibility of unfavorable new
clinical and preclinical data and additional analyses of existing
data, as well as the risks that prior clinical and preclinical
results may not be replicated. These risks and uncertainties
include, but may not be limited to, those described in our Annual
Report on Form 10-K filed with the SEC on March 18,
2019, and in any subsequent filings with the SEC.
Forward-looking statements speak only as of the date of this press
release, and we undertake no obligation to review or update any
forward-looking statement except as may be required by applicable
law.
SOURCE: Innovate Biopharmaceuticals, Inc.
Contact: Jennifer K. Zimmons, Ph.D. Investor
Relations Tel: +1-917-214-3514 Email:
jzimmons@innovatebiopharma.com www.innovatebiopharma.com
Innovate Biopharmaceutic... (NASDAQ:INNT)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Innovate Biopharmaceutic... (NASDAQ:INNT)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024